Related Experiment Video
Updated: Oct 19, 2025

10:21
A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions
Published on: March 3, 2023
1.8K
A New Insight on Exophytic Serous Borderline Adnexal Tumors: Specific Sonographic Features
Leila Haddad1,2, Nir Kugelman2,3, Israel Shapiro1
1Obstetrics and Gynecology Ultrasound Unit, Bnai-Zion Medical Center, Haifa, Israel.
Summary
Exophytic serous borderline ovarian tumors (ESBOT) can mimic high-grade serous carcinoma (HGSC). Specific sonographic features, including unique vascular patterns on color Doppler, help differentiate ESBOT from HGSC for better treatment planning.
Area of Science:
- Gynecologic oncology
- Medical imaging
- Ovarian pathology
Background:
- Exophytic serous borderline ovarian tumors (ESBOT) share sonographic similarities with high-grade serous carcinoma (HGSC).
- Accurate differentiation is crucial for appropriate patient management and surgical planning.
Purpose of the Study:
- To characterize and compare the sonographic features of ESBOT and HGSC.
- To identify specific imaging markers for distinguishing between these two ovarian tumor types.
Main Methods:
- Retrospective analysis of sonographic imaging in seven ESBOT and ten HGSC cases with exophytic growth patterns.
- Characterization of masses using International Ovarian Tumor Analysis (IOTA) terms and color Doppler assessment.
Main Results:
- ESBOT cases showed unilateral irregular solid masses with clear ovarian demarcation, tiny cystic inclusions, and calcifications.
- A unique intratumoral vascular bundle with radial blood flow was observed in ESBOT, absent in HGSC (P < .001).
- ESBOT frequently presented with unilocular-solid components (42.8%), while HGSC predominantly showed multilocular-solid morphology (P < .001).
Conclusions:
- ESBOT exhibits distinct B-mode and color Doppler sonographic features that differentiate it from HGSC.
- These sonographic characteristics can aid in preoperative diagnosis and guide intervention strategies for ovarian tumors.

